Inside informationFrench
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ose Immunotherapeutics
- Filed
- 21/01/2026, 18:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- French
- AMF reference
- 130445_20260121